News
8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

 Read the full interview:

Download DocumentDokument herunterladenSwitzerland Global EnterpriseSwitzerland Global Enterprise
2.11.23
News

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juviv Inc.

Read more
15.10.21
Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

Read more
3.7.20
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more

Investors

InvestorsNews & Events

About us

VisionLeadershipBoard of DirectorsHistoryResearch Partners

Pipeline

Wound HealingSkin FibrosisOphthalmologyMedical cosmetics
OncologyLung Fibrosis
‍

Contact

info@topadur.com+41 44 755 44 66
Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
ImpressumLegal Disclaimer